Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Snapshots of recent studies on VEGF Trap presented at the ARVO meeting

May 4, 2006

Silencing RTP801 gene with novel siRNA shows benefit in a murine model of CNV

May 4, 2006

RTK inhibition reduces retinal vascular permeability in animal models of diabetic macular edema

May 4, 2006

Studies assess ranibizumab alone and with verteporfin PTD in macular degeneration

May 4, 2006

Recent patents claim novel therapeutic agents for ocular disorders

May 3, 2006

Pre-NDA meeting for AzaSite

May 3, 2006

Genaera updates findings from phase II trials of Evizon

May 2, 2006

Alcon and Amgen collaborate on therapeutics for eye diseases

April 26, 2006

Pathogenics licenses N-chlorotaurine rights to Acuity

April 25, 2006

End of phase II testing of diquafosol in Asia triggers milestone payment

April 24, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Elixirgen and Nippon Shinyaku sign EXG-7001 option agreement
BioWorld Science
Elixirgen Therapeutics Inc. has entered into an option agreement with Nippon Shinyaku Co. Ltd. for the development and commercialization of EXG-7001 for Duchenne...
Investors bet on transformative BCI tech for neuro disorders
BioWorld
An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue....